A triazole antifungal
Related Products
Pro-drug Form(s)
42133Fosravuconazole (L-lysine ethanolate)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ravuconazole

Item No. 18750

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-benzonitrile
CAS Number
182760-06-1
Synonyms
  • BMS 207147
  • ER-30346
Molecular Formula
C22H17F2N5OS
Formula Weight
437.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMF:PBS (pH 7.2) (1:4): 0.25 mg/mlDMSO: 20 mg/mlEthanol: 5 mg/ml
λmax
285 nm
SMILES
FC(C=C(F)C=C1)=C1[C@](CN2N=CN=C2)(O)[C@@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3
InChi Code
InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
InChi Key
OPAHEYNNJWPQPX-RCDICMHDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $49

    Add

    5 mg

    $120

    Add

    10 mg

    $213

    Add

    25 mg

    $469

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Ravuconazole is an orally available triazole fungicide that potently inhibits the growth of a wide range of fungi (MICs range from 25 to 780 ng/ml).1,2 Like other azoles, ravuconazole inhibits cytochrome P450 (CYP) isoforms that are involved in ergosterol biosynthesis, interfering with the generation of the fungal and protozoan cell membranes.3 Ravuconazole specifically inhibits sterol 14α-demethylase (CYP51).4,5 As this enzyme is also important in the development of trypanosomes, ravuconazole is effective against T. cruzi infections in animal models of Chagas disease.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hata, K., Kimura, J., Miki, H., et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. 40(10), 2237-2242 (1996).

    2. Hata, K., Kimura, J., Miki, H., et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 40(10), 2243-2247 (1996).

    3. Carillo-Muñoz, A.J., Giusiano, G., Ezkurra, P.A., et al. Antifungal agents: mode of action in yeast cells. Rev.Esp.Quimioter. 19(2), 130-139 (2006).

    4. Urbina, J.A., Payares, G., Sanoja, C., et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int.J.Antimicrob.Agents 21(1), 27-38 (2003).

    5. Lepsheva, G.I. Design or screening of drugs for the treatment of Chagas disease: What shows the most promise? Expert Opin.Drug Discov. 8(12), 1479-1489 (2013).